These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36739240)

  • 41. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
    VanDevanter DR; Zemanick ET; Konstan MW; Ren CL; Odem-Davis K; Emerman I; Young J; Mayer-Hamblett N;
    J Cyst Fibros; 2023 Jul; 22(4):652-655. PubMed ID: 37100705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
    Drummond D; Dana J; Berteloot L; Schneider-Futschik EK; Chedevergne F; Bailly-Botuha C; Nguyen-Khoa T; Cornet M; Le Bourgeois M; Debray D; Girard M; Sermet-Gaudelus I
    J Cyst Fibros; 2022 Mar; 21(2):212-219. PubMed ID: 34454846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies.
    Desai M; Hine C; Whitehouse JL; Brownlee K; Charman SC; Nagakumar P
    Respir Med; 2022 Aug; 199():106878. PubMed ID: 35633605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.
    Almulhem M; Harnett N; Graham S; Haq I; Visram S; Ward C; Brodlie M
    BMJ Open Respir Res; 2022 Oct; 9(1):. PubMed ID: 36207030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
    Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
    [No Abstract]   [Full Text] [Related]  

  • 49. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre.
    Tewkesbury DH; Athwal V; Bright-Thomas RJ; Jones AM; Barry PJ
    J Cyst Fibros; 2023 Mar; 22(2):256-262. PubMed ID: 36669962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current prices versus minimum costs of production for CFTR modulators.
    Guo J; Wang J; Zhang J; Fortunak J; Hill A
    J Cyst Fibros; 2022 Sep; 21(5):866-872. PubMed ID: 35440408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
    Hoy SM
    Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.
    Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F
    Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
    Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
    Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
    Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine.
    Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E
    J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
    Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
    Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of CFTR Modulators for Cystic Fibrosis in a Patient with Liver Transplant and ESRD on Hemodialysis.
    Hu L; Bruno PF; Signorotti S; Ruggeri M; Sgarlato V; Zanchelli F; Neri L; Giudicissi A; Mosconi G
    G Ital Nefrol; 2024 Feb; 41(1):. PubMed ID: 38426679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.